万泰生物(603392) - 2024 Q2 - 季度业绩预告

Financial Performance Expectations - The company expects a net profit attributable to shareholders for the first half of 2024 to be between 240 million and 290 million CNY, a decrease of 146.236 million to 141.236 million CNY compared to the same period last year, representing a year-on-year decline of 85.90% to 82.96%[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between 58 million and 70 million CNY, a decrease of 156.517 million to 155.317 million CNY compared to the same period last year, representing a year-on-year decline of 96.43% to 95.69%[3]. - The total profit for the same period last year was 193.466 million CNY, with a net profit attributable to shareholders of 170.236 million CNY and a net profit after deducting non-recurring gains and losses of 162.317 million CNY[4]. Revenue Forecast - The company anticipates revenue for the second quarter of 2024 to be between 55 million and 68 million CNY, a year-on-year decrease of approximately 56.93% to 46.75%[4]. - The decline in revenue is primarily attributed to the impact of market competition and inventory reduction on the sales of the bivalent HPV vaccine, while the diagnostic segment maintains stable growth due to ongoing projects and collaborations with top hospitals[4]. Earnings Forecast Assurance - The earnings forecast has not been audited by registered accountants, and the final financial data will be disclosed in the official half-year report[3]. - The company assures that there are no significant uncertainties affecting the accuracy of this earnings forecast[4].